By DENNIS J. SELKOEOCTOBER 23, 2019: One of the many things I’ve learned during four decades of doing research on Alzheimer’s disease is that the work always brings surprises. Biogen’s announcement on Tuesday about its experimental Alzheimer’s drug, aducanumab, was a big one. Read the complete article in STAT here.
- ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus May 28, 2020
- ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform May 20, 2020
- ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assay May 19, 2020